Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

NCT ID: NCT05252546

Last Updated: 2022-12-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-08
• Study Completion Date: 2022-08-02

Brief Summary

The study will assess the effect of anti-diarrhea drug Montmorillonite Power or Loperamide on the single dose pharmacokinetic parameters of pyrotinib in healthy Chinese subjects. The safety of pyrotinib alone and when co-administered with each drug will also be assessed.

Conditions

HER2-positive Recurrent / Metastatic Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

pyrotinib alone, then pyrotinib + Montmorillonite Power or Loperamide

Sequential treatments of pyrotinib alone followed by pyrotinib + Montmorillonite Power or Loperamide, with a washout period in between.

Group Type: EXPERIMENTAL

pyrotinib tablet

Intervention Type: DRUG

single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide

Montmorillonite Power

Intervention Type: DRUG

3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration

Loperamide

Intervention Type: DRUG

4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day

Interventions

pyrotinib tablet

single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide

Intervention Type: DRUG

Montmorillonite Power

3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration

Intervention Type: DRUG

Loperamide

4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions.

2. Able to complete the study as required by the protocol.

3. Healthy male and female subjects aged 18 to 45 years on the day of signing the informed consent form; appropriate proportion of subjects of different genders (no less than 3 of single gender) required in both groups A and B.

4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 ~ 26 kg/m2.

5. Subjects of childbearing potential and their partners have no birth plan and voluntarily take effective contraception during the course of clinical trial until 3 months after the last dose (Female subjects are also required to use highly effective non-drug contraception starting two weeks before study entry and can use contraceptives after study completion).

Exclusion Criteria

1. Blood donation no less than 400 mL or have blood transfusion within 3 months of dosing.

2. History of significant hypersensitivity, intolerance, or allergy to any drug compound or known allergy to pyrotinib, montmorillonite power, loperamide or the excipients;

3. History of drug abuse in the past 5 years, or positive for drug abuse screening;

4. History of alcoholism with alcohol consumption over 14 units per week; heavy smoker; and can't abstain from smoking and alcohol during the study

5. QTcF >470 msec for females or >450 msec for males by 12 lead electrocardiograph;

6. Left ventricular ejection fraction (LVEF) <50% by echocardiography

7. Significant history or clinical manifestation of any neurological, cardiovascular, renal, gastrointestinal, pulmonary, respiratory, metabolic and musculoskeletal disorder, as determined by the Investigator (or designee).

8. Any surgery within 6 months before screening;

9. Intake of hepatotoxic drugs for a long time within 6 months before screening;

10. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months;

11. Subjects who took any drugs that change liver enzymes activity within 28 days before dosing;

12. Subjects who took any prescription drugs, over-the-counter drugs or vitamins, health products or herbal medicine within 14 days before dosing;

13. Clinically significant abnormalities as determined by the Investigator (or designee) in general physical examination, vital signs, laboratory tests, etc.

14. Pregnant or lactating females

15. Positive serology test results for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or human immunodeficiency virus antibody.

16. Subjects who took any beverage or food containing grapefruit, xanthine, caffeine, or alcohol within 48 hours before dosing; strenuous exercise; or other factors which affect drug absorption, distribution, metabolism, excretion, etc

17. Subjects who need to avoid inhibiting intestinal peristalsis, such as patients with flatulence or constipation, or gastrointestinal symptoms such as diarrhea, dry mouth, abdominal distension, anorexia, gastrointestinal spasm, nausea, vomiting, as well as dizziness, headache and fatigue;

18. Those who have special requirements for diet and cannot comply with the diet and corresponding requirements provided by the trial;

19. Those who cannot tolerate venipuncture or with a history of needle-sickness and blood-sickness.

20. Those who have received a live vaccine 2 weeks prior to dosing or are scheduled to be vaccinated within 7 days after study completion.

21. Subjects who, in the opinion of the Investigator should not participate in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Xiangya Hospital Central South University

Changsha, Hunan, China

Countries

China

References

Wang Y, Li D, Zhang T, Xu S, Zhang Y, Zhao K, Li S, Shen K, Li X, Xu P. Evaluation of the pharmacokinetic interactions of montmorillonite powder or loperamide on pyrotinib in healthy volunteers. Front Pharmacol. 2025 May 12;16:1563556. doi: 10.3389/fphar.2025.1563556. eCollection 2025.

Reference Type: DERIVED

PMID: 40433999 (View on PubMed)

Other Identifiers

HR-BLTN-DDI-07

Identifier Type: -

Identifier Source: org_study_id